Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 171

1.

HER-2/neu assessment in breast cancer using the original FDA and new ASCO/CAP guideline recommendations: impact on selecting patients for herceptin therapy.

Brunelli M, Manfrin E, Martignoni G, Bersani S, Remo A, Reghellin D, Chilosi M, Bonetti F.

Am J Clin Pathol. 2008 Jun;129(6):907-11. doi: 10.1309/MD79CDXN1D01E862.

2.

Genotypic intratumoral heterogeneity in breast carcinoma with HER2/neu amplification: evaluation according to ASCO/CAP criteria.

Brunelli M, Manfrin E, Martignoni G, Miller K, Remo A, Reghellin D, Bersani S, Gobbo S, Eccher A, Chilosi M, Bonetti F.

Am J Clin Pathol. 2009 May;131(5):678-82. doi: 10.1309/AJCP09VUTZWZXBMJ.

4.

Simultaneous detection of HER2/neu gene amplification and protein overexpression in paraffin-embedded breast cancer.

Lottner C, Schwarz S, Diermeier S, Hartmann A, Knuechel R, Hofstaedter F, Brockhoff G.

J Pathol. 2005 Apr;205(5):577-84.

PMID:
15732132
5.

Her-2/neu and topoisomerase IIα in advanced breast cancer: a comprehensive FISH analysis of 245 cases.

Engelstaedter V, Schiffers J, Kahlert S, Mainka P, Engel J, Kirchner T, Diebold J, Mayr D.

Diagn Mol Pathol. 2012 Jun;21(2):77-83. doi: 10.1097/PDM.0b013e31823b6e43.

PMID:
22555090
6.

Assessment of HER-2/neu overexpression and/or gene amplification in breast carcinomas: should in situ hybridization be the method of choice?

Sauer T, Wiedswang G, Boudjema G, Christensen H, Karesen R.

APMIS. 2003 Mar;111(3):444-50.

PMID:
12752225
7.
8.

Correlation of her-2/neu gene amplification with other prognostic and predictive factors in female breast carcinoma.

Ariga R, Zarif A, Korasick J, Reddy V, Siziopikou K, Gattuso P.

Breast J. 2005 Jul-Aug;11(4):278-80.

PMID:
15982396
9.

Her-2/neu and breast cancer.

Kaptain S, Tan LK, Chen B.

Diagn Mol Pathol. 2001 Sep;10(3):139-52. Review.

PMID:
11552716
10.

Assessment of HER2/Neu status by fluorescence in situ hybridization in immunohistochemistry-equivocal cases of invasive ductal carcinoma and aberrant signal patterns: a study at a tertiary cancer center.

Murthy SS, Sandhya DG, Ahmed F, Goud KI, Dayal M, Suseela K, Rajappa SJ.

Indian J Pathol Microbiol. 2011 Jul-Sep;54(3):532-8. doi: 10.4103/0377-4929.85087.

11.

Her-2/neu-triggered intracellular tyrosine kinase activation: in vivo relevance of ligand-independent activation mechanisms and impact upon the efficacy of trastuzumab-based treatment.

Hudelist G, Köstler WJ, Attems J, Czerwenka K, Müller R, Manavi M, Steger GG, Kubista E, Zielinski CC, Singer CF.

Br J Cancer. 2003 Sep 15;89(6):983-91.

12.

Prediction of HER2 gene status in Her2 2+ invasive breast cancer: a study of 108 cases comparing ASCO/CAP and FDA recommendations.

Chibon F, de Mascarel I, Sierankowski G, Brouste V, Bonnefoi H, Debled M, Mauriac L, MacGrogan G.

Mod Pathol. 2009 Mar;22(3):403-9. doi: 10.1038/modpathol.2008.195.

13.

Clinical and health economic outcomes of alternative HER2 test strategies for guiding adjuvant trastuzumab therapy.

Lee JA, Shaheen M, Walke T, Daly M.

Expert Rev Pharmacoecon Outcomes Res. 2011 Jun;11(3):325-41. doi: 10.1586/erp.11.25. Review.

PMID:
21671702
14.

Adjuvant therapy with trastuzumab for HER-2/neu-positive breast cancer.

Gonzalez-Angulo AM, Hortobágyi GN, Esteva FJ.

Oncologist. 2006 Sep;11(8):857-67. Review.

15.

Accurately assessing her-2/neu status in needle core biopsies of breast cancer patients in the era of neoadjuvant therapy: emerging questions and considerations addressed.

D'Alfonso T, Liu YF, Monni S, Rosen PP, Shin SJ.

Am J Surg Pathol. 2010 Apr;34(4):575-81. doi: 10.1097/PAS.0b013e3181d65639.

PMID:
20216378
16.

Targeted therapy for cancer: the HER-2/neu and Herceptin story.

Ross JS, Gray GS.

Clin Leadersh Manag Rev. 2003 Nov-Dec;17(6):333-40. Review.

PMID:
14692077
18.
19.

Impact of American Society of Clinical Oncology/College of American Pathologists guideline recommendations on HER2 interpretation in breast cancer.

Shah SS, Ketterling RP, Goetz MP, Ingle JN, Reynolds CA, Perez EA, Chen B.

Hum Pathol. 2010 Jan;41(1):103-6. doi: 10.1016/j.humpath.2009.07.001.

PMID:
19762065
20.

HER2/neu gene amplification and protein overexpression in G3 pT2 transitional cell carcinoma of the bladder: a role for anti-HER2 therapy?

Latif Z, Watters AD, Dunn I, Grigor K, Underwood MA, Bartlett JM.

Eur J Cancer. 2004 Jan;40(1):56-63.

PMID:
14687790
Items per page

Supplemental Content

Support Center